Onderzoeker
Thomas Billiet
- Disciplines:Endocrinologie en metabole ziekten, Gastro-enterologie en hepatologie, Ontdekking en evaluatie van biomarkers, Ontdekking en evaluatie van geneesmiddelen, Medicinale producten, Farmaceutica, Farmacognosie en fytochemie, Farmacologie, Farmacotherapie, Toxicologie en toxinologie, Andere farmaceutische wetenschappen
Affiliaties
- Translationeel Onderzoek van Gastro-enterologische Aandoeningen (TARGID) (Afdeling)
Lid
Vanaf1 aug 2012 → 31 jul 2016
Publicaties
1 - 10 van 27
- Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment(2017)
Auteurs: Lucas Wauters, Thomas Billiet, Vera Ballet, Steven Joniau, Patrick Verschueren, Gert Van Assche, Séverine Vermeire, Marc Ferrante
Pagina's: 84 - 90 - A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease(2016)
Auteurs: Thomas Billiet, Erwin Dreesen, Isabelle Cleynen, Marc Ferrante, Gert Van Assche, Ann Gils, Séverine Vermeire
Pagina's: 1438 - 1445 - Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab(2016)
Auteurs: Thomas Billiet, Niels Vande Casteele, Ann Gils, Marc Ferrante, Gert Van Assche, Paul Rutgeerts, Séverine Vermeire
Pagina's: 1015 - 1023 - The Need for Surgery in Stricturing Ileal CD Is Linked to Clinical and Imaging Factors But Independent of NOD2 Genotype(2016)
Auteurs: Peter Bossuyt, Celine Debeuckelaere, Thomas Billiet, Isabelle Cleynen, Anthony de Buck van Overstraeten, Albert Wolthuis, Marc Ferrante, Gert Van Assche, André D'Hoore, Séverine Vermeire
Pagina's: S560 - S560 - Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis(2016)
Auteurs: Thomas Van Stappen, Niels Vande Casteele, Ann Gils, Thomas Billiet, Gert Van Assche, Paul Rutgeerts, Séverine Vermeire, Marc Ferrante
Pagina's: 543 - 549 - Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study(2016)
Auteurs: Isabelle Cleynen, Thomas Billiet, Niels Vande Casteele, Christine Breynaert, Vera Ballet, Marc Ferrante, Gert Van Assche, Paul Rutgeerts, Joost van den Oord, Ann Gils, et al.
Pagina's: 10 - 22 - A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease(2015)
Auteurs: Thomas Billiet, Magali de Bruyn, Bram Verstockt, Isabelle Cleynen, Marc Ferrante, Gert Van Assche, Séverine Vermeire
Pagina's: 1120 - 6 - An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases(2015)
Auteurs: Thomas Van Stappen, Thomas Billiet, Niels Vande Casteele, Séverine Vermeire, Ann Gils
Pagina's: 2172 - 2177 - Immunogenicity to infliximab is associated with HLA-DRB1(2015)
Auteurs: Thomas Billiet, Niels Vande Casteele, Thomas Van Stappen, Ann Gils, Marc Ferrante, Gert Van Assche, Isabelle Cleynen, Séverine Vermeire
Pagina's: 1344 - 5 - Early Therapeutic Drug Monitoring for Prediction of Short- Term Mucosal Healing in Patients With Ulcerative Colitis Treated With Infliximab(2015)
Auteurs: Konstantinos Papamichael, Niels Vande Casteele, Thomas Billiet, Ann Gils, Sophie Tops, Karolien Claes, Gert Van Assche, Paul Rutgeerts, Séverine Vermeire, Marc Ferrante
Pagina's: S848 - S848